BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35973802)

  • 1. Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission.
    Gamerith G; Mildner F; Merkel PA; Harris K; Cooney L; Lim N; Spiera R; Seo P; Langford CA; Hoffman GS; St Clair EW; Fervenza FC; Monach P; Ytterberg SR; Geetha D; Amann A; Wolf D; Specks U; Stone JH; Kronbichler A
    Ann Rheum Dis; 2023 Feb; 82(2):253-261. PubMed ID: 35973802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.
    Berti A; Warner R; Johnson K; Cornec D; Schroeder DR; Kabat BF; Langford CA; Kallenberg CGM; Seo P; Spiera RF; St Clair EW; Fervenza FC; Stone JH; Monach PA; Specks U; Merkel PA;
    J Autoimmun; 2019 Dec; 105():102302. PubMed ID: 31320177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
    Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
    Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Pepper RJ; Draibe JB; Caplin B; Fervenza FC; Hoffman GS; Kallenberg CG; Langford CA; Monach PA; Seo P; Spiera R; William St Clair E; Tchao NK; Stone JH; Specks U; Merkel PA; Salama AD;
    Arthritis Rheumatol; 2017 Jan; 69(1):185-193. PubMed ID: 27428710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
    Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
    Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
    Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
    Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.
    Fussner LA; Hummel AM; Schroeder DR; Silva F; Cartin-Ceba R; Snyder MR; Hoffman GS; Kallenberg CG; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; William St Clair E; Tchao NK; Stone JH; Specks U;
    Arthritis Rheumatol; 2016 Jul; 68(7):1700-10. PubMed ID: 26882078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis.
    McClure ME; Wason J; Gopaluni S; Tieu J; Smith RM; Jayne DR; Jones RB
    J Clin Rheumatol; 2019 Aug; 25(5):217-223. PubMed ID: 30896460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis.
    Thompson GE; Fussner LA; Hummel AM; Schroeder DR; Silva F; Snyder MR; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; St Clair EW; Stone JH; Specks U
    Front Immunol; 2020; 11():2053. PubMed ID: 33013868
    [No Abstract]   [Full Text] [Related]  

  • 10. PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab.
    van Dam LS; Dirikgil E; Bredewold EW; Ray A; Bakker JA; van Kooten C; Rabelink TJ; Teng YKO
    Nephrol Dial Transplant; 2021 Jul; 36(8):1408-1417. PubMed ID: 32601673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Wallace ZS; Fu X; Liao K; Kallenberg CGM; Langford CA; Merkel PA; Monach P; Seo P; Specks U; Spiera R; St Clair EW; Zhang Y; Choi H; Stone JH
    Arthritis Rheumatol; 2019 Nov; 71(11):1879-1887. PubMed ID: 31162829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited.
    Bensalem A; Mulleman D; Paintaud G; Azzopardi N; Gouilleux-Gruart V; Cornec D; Specks U; Ternant D
    Clin Pharmacokinet; 2020 Apr; 59(4):519-530. PubMed ID: 31586310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Berti A; Hillion S; Konig MF; Moura MC; Hummel AM; Carmona E; Peikert T; Fervenza FC; Kallenberg CGM; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; Brunetta P; St Clair EW; Harris KM; Stone JH; Grandi G; Pers JO; Specks U; Cornec D
    Arthritis Rheumatol; 2023 May; 75(5):736-747. PubMed ID: 36281741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and prognostic features of Korean patients with MPO-ANCA, PR3-ANCA and ANCA-negative vasculitis.
    Yoo J; Kim HJ; Ahn SS; Jung SM; Song JJ; Park YB; Lee SW
    Clin Exp Rheumatol; 2017; 35 Suppl 103(1):111-118. PubMed ID: 28339364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD14 expression is increased on monocytes in patients with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis and correlates with the expression of ANCA autoantigens.
    Tarzi RM; Liu J; Schneiter S; Hill NR; Page TH; Cook HT; Pusey CD; Woollard KJ
    Clin Exp Immunol; 2015 Jul; 181(1):65-75. PubMed ID: 25766482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort.
    Chasseur P; Blockmans D; von Frenckell C; Nicolas JB; Regniers C; Vandergheynst F
    Acta Clin Belg; 2020 Jun; 75(3):163-169. PubMed ID: 30767717
    [No Abstract]   [Full Text] [Related]  

  • 17. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis.
    Slot MC; Tervaert JW; Boomsma MM; Stegeman CA
    Arthritis Rheum; 2004 Apr; 51(2):269-73. PubMed ID: 15077271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Berti A; Warner R; Johnson K; Cornec D; Schroeder D; Kabat B; Langford CA; Hoffman GS; Fervenza FC; Kallenberg CGM; Seo P; Spiera R; St Clair EW; Brunetta P; Stone JH; Merkel PA; Specks U; Monach PA;
    Arthritis Rheumatol; 2018 Jul; 70(7):1114-1121. PubMed ID: 29693324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features and prognosis of ANCA-associated vasculitis patients who were double-seropositive for myeloperoxidase-ANCA and proteinase 3-ANCA.
    Gong Y; Shen C; Meng T; Lin W; Hu X; Tang R; Xiong Q; Ooi JD; Eggenhuizen PJ; Chen J; Zhou YO; Luo H; Xu J; Liu N; Xiao P; Xiao X; Zhong Y
    Clin Exp Med; 2024 Apr; 24(1):66. PubMed ID: 38564029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial.
    Smith RM; Jones RB; Specks U; Bond S; Nodale M; Al-Jayyousi R; Andrews J; Bruchfeld A; Camilleri B; Carette S; Cheung CK; Derebail V; Doulton T; Ferraro A; Forbess L; Fujimoto S; Furuta S; Gewurz-Singer O; Harper L; Ito-Ihara T; Khalidi N; Klocke R; Koening C; Komagata Y; Langford C; Lanyon P; Luqmani R; McAlear C; Moreland LW; Mynard K; Nachman P; Pagnoux C; Peh CA; Pusey C; Ranganathan D; Rhee RL; Spiera R; Sreih AG; Tesar V; Walters G; Wroe C; Jayne D; Merkel PA;
    Ann Rheum Dis; 2023 Jul; 82(7):937-944. PubMed ID: 36958796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.